Potassium canrenoate Property

Melting point:

242-244°C (dec.)

Density 

1.345 g/cm3

storage temp. 

Refrigerator

solubility 

Methanol (Slightly)

form 

powder

color 

light yellow to tan

CAS DataBase Reference

2181-04-6(CAS DataBase Reference)

Safety

Hazard Codes 

Xn

Risk Statements 

22

Safety Statements 

36

WGK Germany 

3

RTECS 

TU3500000

Toxicity

LD50 oral in rat: 650mg/kg

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P330Rinse mouth.

Potassium canrenoate Chemical Properties,Usage,Production

Originator

Spiroctan,Boehringer Mannheim,Switz.,1968

Uses

Canrenoic acid is an aldosterone antagonist. Canrenoic acid is used as an diuretic.

Uses

anticholithogenic, antilipemic agent

Manufacturing Process

The lactone is prepared as follows: A solution of 5 parts of 17α-carboxyethyl- 17β-hydroxyandrost-4-en-3-one lactone and 5 parts of chloranil in 400 parts of xylene containing a trace of p-toluenesulfonic acid is heated at the boiling point of the solvent under reflux overnight. The solution is then cooled and filtered through approximately 200 parts of silica gel. The gel is successively washed with 5%, 10%, and 15% ethyl acetate-benzene solutions, and the washings comprising 15% ethyl acetate are thereupon purified by chromatography on a further quantity of silica gel, using benzene and ethyl acetate as developing solvents. From the 15% ethyl acetate eluate there is obtained pure 17α-carboxyethyl-17β-hydroxyandrost-4,6-dien-3-one lactone, melting at 148° to 151°C. The product solidifies above this melting point and melts again at 165°C.

brand name

Aldactone-diurapid;Aldadiene potassium;Kadiur;Lasiren;Luvion;Osirenol;Osyrol-lasix;Phanurane;Sincomen pro injectione;Speroctan-m;Spiroctan.

Therapeutic Function

Aldosterone antagonist, Diuretic

World Health Organization (WHO)

Potassium canrenoate, which has no intrinsic aldosterone antagonist activity, owes its therapeutic effect to the enzymatic interconversion in the body to canrenone. Evidence that long-term administration of high doses are tumorigenic in the rat has recently led to restriction of its use by some national regulatory authorities. See also WHO comments for canrenone and spironolactone.